Royalty Pharma plc
RPRXNasdaqHealthcare · Pharmaceutical Preparations · X0 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $2.38B | $2.26B | $2.35B | $2.24B | $2.29B | $2.12B |
| Operating income | $1.56B | $1.29B | $1.49B | $307.1M | $1.43B | $1.60B |
| Net income | $770.9M | $859.0M | $1.13B | $42.8M | $619.7M | $975.0M |
| Total assets | $19.62B | $18.22B | $16.38B | $16.81B | $17.52B | $16.02B |
| Total liabilities | $9.91B | $7.88B | $6.30B | $7.29B | $7.27B | $6.12B |
| Equity | $9.71B | $10.34B | $10.08B | $9.53B | $10.25B | $9.90B |
| EPS (diluted) | $1.78 | $1.91 | $2.53 | $0.10 | $1.49 | $1.32 |
| Shares out. | 564.5M | 594.1M | 602.9M | 438.0M | 414.8M | 375.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 65.6%
- Net margin
- 32.4%
- Return on equity
- 7.9%
- Return on assets
- 3.9%
- Return on capital (ROCE)
- 8.2%
- Liabilities / assets
- 50.5%
- Debt / equity
- 1.02×
- Book value / share
- $17.21
- Revenue growth (YoY)
- 5.1%
- Net income growth (YoY)
- −10.2%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 2.25grey zone
- Accruals / assets
- −8.8%clean
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 warning● 4 good- Altman Z″ in the grey zone
- Operating margin is positive
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Capital International InvestorsPassive (13G)May 14, 2026
- Severgnini Achille G.Activist (13D)Feb 20, 2026
- Fmr LlcPassive (13G)Nov 5, 2025
- Vanguard Group IncPassive (13G)Oct 30, 2025
- General Atlantic, L.P.Passive (13G)Aug 14, 2025
- Morgan StanleyPassive (13G)Aug 5, 2025
- Legorreta Pablo G.Activist (13D)May 23, 2025
- Blackrock, Inc.Passive (13G)Feb 4, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 12.7M | 3.3 | -8.2% |
| Apr 30, 2026 | 13.8M | 4.4 | +15.0% |
| Apr 15, 2026 | 12.0M | 4.4 | +4.3% |
| Mar 31, 2026 | 11.5M | 3.3 | -0.5% |
| Mar 13, 2026 | 11.6M | 3.4 | -4.8% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · New financial obligationMay 28, 2026
- Results of operationsMay 6, 2026
- Regulation FD disclosureApr 13, 2026
- Results of operationsFeb 11, 2026
- Director / officer changeDec 22, 2025
- Regulation FD disclosureDec 22, 2025
- Results of operationsNov 5, 2025
- Entered a material agreement · Other material eventSep 16, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.